219 related articles for article (PubMed ID: 30909370)
1. Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report.
Gualtierotti R; De Lucia O
J Clin Med; 2019 Mar; 8(3):. PubMed ID: 30909370
[TBL] [Abstract][Full Text] [Related]
2. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
3. Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.
Mease PJ
Rheumatol Ther; 2014 Dec; 1(1):1-20. PubMed ID: 27747762
[TBL] [Abstract][Full Text] [Related]
4. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study.
Sfikakis PP; Vassilopoulos D; Katsifis G; Vosvotekas G; Dimitroulas T; Sidiropoulos P; Vounotrypidis P; Bogdanos DP; Georgountzos AΙ; Bounas AG; Georgiou P; Gazi S; Kataxaki E; Liossis SN; Theodorou E; Papagoras C; Theotikos E; Vlachoyiannopoulos P; Voulgari PV; Kekki A; Antonakopoulos N; Boumpas DT
Rheumatol Int; 2023 May; 43(5):889-902. PubMed ID: 36856816
[TBL] [Abstract][Full Text] [Related]
5. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
[TBL] [Abstract][Full Text] [Related]
6. Apremilast for the treatment of psoriatic arthritis.
Souto A; Gómez-Reino JJ
Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
[TBL] [Abstract][Full Text] [Related]
7. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
Abdulrahim H; Thistleton S; Adebajo AO; Shaw T; Edwards C; Wells A
Expert Opin Pharmacother; 2015 May; 16(7):1099-108. PubMed ID: 25864487
[TBL] [Abstract][Full Text] [Related]
8. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Deeks ED
Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
[TBL] [Abstract][Full Text] [Related]
9. Update on the treatment of psoriasis and psoriatic arthritis - role of apremilast.
Forchhammer S; Ghoreschi K
Psoriasis (Auckl); 2015; 5():117-124. PubMed ID: 29387588
[TBL] [Abstract][Full Text] [Related]
10. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
11. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
[TBL] [Abstract][Full Text] [Related]
12. Safety evaluation of apremilast for the treatment of psoriasis.
Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
Gladman DD; Kavanaugh A; Gómez-Reino JJ; Wollenhaupt J; Cutolo M; Schett G; Lespessailles E; Guerette B; Delev N; Teng L; Edwards CJ; Birbara CA; Mease PJ
RMD Open; 2018; 4(1):e000669. PubMed ID: 30018799
[TBL] [Abstract][Full Text] [Related]
14. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
[TBL] [Abstract][Full Text] [Related]
15. Apremilast in the treatment of psoriasis and psoriatic arthritis.
Gooderham M; Papp K
Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
[TBL] [Abstract][Full Text] [Related]
17. Expert recommendations for the use of apremilast in psoriatic arthritis.
Torre Alonso JC; Almodóvar González R; Montilla Morales C; Sanz Sanz J; Díaz González F; Pascual Alfonso E; Gratacós J
Reumatol Clin (Engl Ed); 2023 Jan; 19(1):34-44. PubMed ID: 35537933
[TBL] [Abstract][Full Text] [Related]
18. Apremilast in psoriatic arthritis.
Schett G
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
[TBL] [Abstract][Full Text] [Related]
19. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Schafer P
Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
[TBL] [Abstract][Full Text] [Related]
20. Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
Haber SL; Hamilton S; Bank M; Leong SY; Pierce E
Ann Pharmacother; 2016 Apr; 50(4):282-90. PubMed ID: 26783350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
